Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

60%

3 trials in Phase 3/4

Results Transparency

0 of 5 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A

2(40.0%)

Phase 4

2(40.0%)

Phase 3

1(20.0%)

5Total

N/A(2)

Phase 4(2)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT05635201Phase 3Completed

Changes in Autonomic Nervous Activity and Blood Pressure After Anesthesia Induction: Remimazolam Versus Propofol

Role: collaborator

NCT05047939Not ApplicableCompleted

Comparison of Recovery Profile After TIVA Between Remimazolam With Flumazenil and Propofol

Role: collaborator

NCT05356091Not ApplicableCompleted

Quality of Recovery of Remimazolam Versus Sevoflurane in Transurethral Bladder Resection.

Role: collaborator

NCT05423080Phase 4Completed

Anesthesia Induction With Intravenous Bolus or Continuous Infusion of Remimazolam

Role: collaborator

NCT01404689Phase 4Completed

Study to Determine if the Midazolam-Meperidine-Dexmedetomidine is Superior to the Midazolam-Meperidine for Sedation During ERCP

Role: collaborator

All 5 trials loaded